PharmaBoardroom

Aducanumab edges closer to Potential Approval: Next up, the…

In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…

Emerging Markets: How COVID-19 is Throwing New Light on the Role…

Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight,…

Alan Knox – Group CEO, Primex Pharmaceuticals

Alan Knox of Primex Pharmaceuticals explains how the COVID-19 pandemic has thrust the anaesthesia field back into the global spotlight, the benefits…

Four Cell & Gene Companies to Know in China

While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese…

Importing Drugs from Canada: America’s Zombieland Sequel

Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain…

PhRMA CEO on ‘Tireless’ Industry COVID-19 Response &…

Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded…

Abdi Ibrahim Buys 28.5% Stake in Swiss OM; A Historic Moment for…

When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey's pharma…

Mexico Looks to India to Bolster Domestic Supply Chain post-COVID

COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has…

Stephen Farr – President & CEO, Zogenix

Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into…

Renée C. Amundsen – Global Head of Business Innovation,…

Merck Healthcare’s newly appointed Global Head of Business innovation, Renée C. Amundsen, highlights the numerous opportunities for change…

Brent Ragans – President, Ferring Pharmaceuticals US

Brent Ragans of Ferring Pharmaceuticals US discusses the effects of the COVID-19 pandemic on the company’s operations, their footprint in…

Cell & Gene Therapy: Command? Consent? Collaborate!

Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the…

Sign in

Tagged with